Article Sidebar

Submitted
Apr 21, 2021
Published
Apr 21, 2021
Download
PDF
Statistic
Read Counter : 55 Download : 27

Main Article Content

Abstract

Hemolysis is a disorder of destruction of RBC cells in our body;chloroquine is the drug that regularly preferred to anti-malarial activity. This current study observes the destruction of RBC cells by chloroquine when treated with malarial disease and control of RBC lysis with addition of green tea extract along with chloroquine. Green tea leaves consist of phenolic compounds like flavonoids and catechin. Due to the presence of flavonoids and catechin which reduce the hemolysis of RBC by oxidative stress. This current study deals with concentration of hemolysis when induced with chloroquine and compared with aqueous extract of green tea with induced chloroquine and RBC suspension. This was clearly done by using the separation of the serum from plasma and induced the chloroquine to RBC suspension then the Heme generated was assayed and also absorbance was seen in UV visible photometry by following concentrations [high (2mg/ml) and low (1mg/ml)] of chloroquine. This same was repeated with addition of aqueous extraction of green tea by same concentration [high (1mg/ml) and low (2mg/ml)]. And observed that hemolysis taken place was 38.27% to 15.3%. (at low concentrations of chloroquine and green tea extract (1 mg/ml)). And also 55.56% to 26.17% (at high concentrations of chloroquine and green tea extract (2mg/ml)).

Keywords

Hemolysis Chloroquine Green tea leaves Oxidative stress

Article Details

How to Cite
Mr. K.P. Raghava Krishna, Asam. Harika, G. Sai Kiranmai, Y. Harshavardhan Reddy, Mr. Kartheek.Ch, & Dr.A.M.S. Sudhakar Babu. (2021). Evaluation of anti-hemolytic activity of green tea aqueous extracts by in vitro method. International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(2), 191-198. https://doi.org/10.61096/ijrpp.v6.iss2.2017.191-198
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Carraro P, Servidio G, Plebani M. Hemolyzed specimens: a reason for rejection or a clinical challenge? ClinChem 46, 2000, 306–7.
  2. [2]. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. J Am Med Assoc 293, 2005, 1653–62.
  3. [3]. Burns ER, Yoshikawa N. Hemolysis in serum samples drawn by emergency department personnel versus laboratory phlebotomists. Lab Med 33, 2002, 378–80.
  4. [4]. Da Silva E, Shahgaldian P, Coleman AW, Haemolytic properties of some water-soluble para-sulphonato-calix-[n]-arenes. Int J Pharm. 273(1-2), 2004, 57-62.
  5. [5]. WHO, MMWR Morb. Mortal Wkly. Rep. 59, 2010, 217.
  6. [6]. S. Mharakurwa, T. Kumwenda, M. A. Mkulama, M. Musapa, S. Chishimba, C. J. Shiff, D. J. Sullivan, P. E. Thuma, K. Liu, and P. Agre, Proc. Natl. Acad. Sci. USA 108, 2011, 18796.
  7. [7]. L. L. Koekemoer, B. L. Spillings, R. N. Christian, T. C. Lo, M. L. Kaiser, R. A. Norton, S. V. Oliver, K. S. Choi, B. D. Brooke, R. H. Hunt, and M. Coetzee, Vector Borne Zoonotic Dis. 11, 2011, 1193.
  8. [8]. F. Astelbauer, M. Gruber, B. Brem, H. Greger, A. Obwaller, G. Wernsdorfer, K. Congpuong, W. H. Wernsdorfer, and J. Walochnik, Acta Trop. 123, 2012, 96.
  9. [9]. S. Sang, J. D. Lambert, C. T. Ho, and C. S. Yang, Pharmacol. Res. 64, 2011, 87.
  10. [10]. K. S. Almurshed, Saudi Med. J. 27, 2006, 1804.
  11. [11]. G. Mikutis, H. Karakose, R. Jaiswal, A. Legresley, T. Islam, M. Fernandez-Lahore, and N. Kuhnert, Food Funct. 2012.
  12. [12]. N. J. Naderi, M. Niakan, M. J. K. Fard, and S. Zardi, J. Dent. (Tehran) 8, 2011, 55.
  13. [13]. V. B. Schini-Kerth, N. Etienne-Selloum, T. Chataigneau, and C. Auger, Planta Med. 77, 2011, 1161.
  14. [14]. J. Halder and A. N. Bhaduri, Biochem. Biophys. Res. Commun. 244, 1998, 903.
  15. [15]. E. Satoh, N. Tohyama, and M. Nishimura, Int. J. Food Sci. Nutr. 56, 2005, 551.
  16. [16]. T. J. Lamb and J. Langhorne, Malar. J. 7, 2008, 68.
  17. [17]. S. M. Ahmed, S. K. Abd Al-Rhim, A. A. Mohamedani, A. B. Habour, and A. A. Sadek, Saudi Med. J. 23, 2002, 684.
  18. [18]. H. U. Okafor and O. Nwaiwu, J. Trop. Pediatr. 47, 2001, 271.
  19. [19]. S. K. Sharma, P. Parasuraman, G. Kumar, N. Surolia, and A. Surolia, J. Med. Chem. 50, 2007, 765.
  20. [20]. A. R. Sannella, L. Messori, A. Casini, F. F. Vincieri, A. R. Bilia, G. Majori, and C. Severini, Biochem. Biophys. Res. Commun. 353, 2007, 177 Chadburn A. The spleen: anatomy and anatomical function. SeminHematol 37(1), 2000, 13-21.
  21. [21]. Walters MC, Abelson HT. Interpretation of the complete blood count. PediatrClin North Am 43, 1996, 599-622.
  22. [22]. Marchand A, Galen S, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA 243, 1980, 1909-11.
  23. [23]. Tabbara IA. Hemolyticanemias. Diagnosis and management. Med Clin North Am 76, 1992, 649-68.
  24. [24]. Gutman JD, Kotton CN, Kratz A. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-2003. A 60-year-old man with fever, rigors, and sweats. N Engl J Med 349, 2003, 1168-75.
  25. [25]. Ucar K. Clinical presentation and management of hemolyticanemias. Oncology [Huntingt] 16(9-10), 2002, 163-70.
  26. [26]. Maedel L, Sommer S. Morphologic changes in erythrocytes. Vol. 4. Chicago: American Society for Clinical Pathology Press, 50, 52,66, 1993.
  27. [27]. Engelfriet CP, Overbeeke MA, von dem Borne AE. Autoimmune hemolyticanemia. SeminHematol 29, 1992, 3-12.
  28. [28]. Jefferies LC. Transfusion therapy in autoimmune hemolyticanemia. HematolOncolClin North Am 8, 1994, 1087-104.
  29. [29]. Schwartz RS, Berkman EM, Silberstein LE. Autoimmune hemolyticanemias. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, et al., eds. Hematology: basic principles and practice. Philadelphia: Churchill Livingstone, 3, 2000, 624.
  30. [30]. Saif MW. HIV-associated autoimmune hemolyticanemia: an update. AIDS Patient Care STDS 15, 2001, 217-24.
  31. [31]. Gehrs BC, Friedberg RC. Autoimmune hemolyticanemia. Am J Hematol 69, 2002, 258-71.
  32. [32]. Petz LD. Drug-induced autoimmune hemolyticanemia. Transfus Med Rev 7, 1993, 242-54.
  33. [33]. Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev 2001, 15:69-83.
  34. [34]. Schrier SL. Extrinsic nonimmunehemolyticanemias. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, et al., eds. Hematology: basic principles and practice. 3d ed. Philadelphia: Churchill Livingstone, 2000, 630-8.
  35. [35]. Berkowitz FE. Hemolysis and infection: categories and mechanisms of their interrelationship. Rev Infect Dis 13, 1991, 1151-62.
  36. [36]. Barrett-Connor E. Anemia and infection. Am J Med 52, 1972, 242- 53.
  37. [37]. Beutler E, Luzzatto L. Hemolyticanemia. SeminHematol 36(4-7), 1999, 38-47.
  38. [38]. Beutler E. G6PD deficiency. Blood 84, 1994, 3613-36.
  39. [39]. Steensma DP, Hoyer JD, Fairbanks VF. Hereditary red blood cell disorders in middle eastern patients. Mayo Clinic Proc 76, 2001, 285-93.
  40. [40]. Bolton-Maggs PH. The diagnosis and management of hereditary spherocytosis. Baillieres Best Pract Res ClinHaematol 13, 2000, 327-42.
  41. [41]. Marchetti M, Quaglini S, Barosi G. Prophylactic splenectomy and cholecystectomy in mild hereditary spherocytosis: analyzing the decision in different clinical scenarios. J Intern Med 244, 1998, 217-26.
  42. [42]. Bader-Meunier B, Gauthier F, Archambaud F, Cynober T, Mielot F, Dommergues JP, et al. Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis. Blood 97, 2001, 399-403.
  43. [43]. Tchernia G, Bader-Meunier B, Berterottiere P, Eber S, Dommergues JP, Gauthier F. Effectiveness of partial splenectomy in hereditary spherocytosis. CurrOpinHematol 4, 1997, 136-41.
  44. [44]. De Buys Roessingh AS, de Lagausie P, Rohrlich P, Berrebi D, Aigrain Y. Follow-up of partial splenectomy in children with hereditary spherocytosis. J PediatrSurg 37, 2002, 1459-63.
  45. [45]. Graham HN. Green tea consumption, composition, and polyphenol chemistry.Preventive Medicine. 21, 1992, 334-50.
  46. [46]. Vinson JA, Dabbagh YA. Effect of green and black tea supplementation on lipids,lipid oxidation and fibrinogen in the hamster: mechanisms for the epidemiological benefits of tea drinking. FEBS Letters. 433(1-2), 1998, 44-6.
  47. [47]. Tijburg LB, Wiseman SA, Meijer GW, Weststrate JA. Effects of green tea, black tea and dietary lipophilic antioxidants on LDL oxidizability and atherosclerosis in hypercholesterolaemic rabbits. Atherosclerosis. 135(1), 1997, 37-47. Nutrition Noteworthy, 2(1,7), 1999.
  48. [48]. Pearson DA, Frankel EN, Aeshbach R, German JB. Inhibition of endothelial cell mediated oxidation of low-density lipoproteins by green tea antioxidants. FASEB Journal. 10, 1996, A476
  49. [49]. Zhang A, Zhu QY, Luk YS, Ho KY, Fung KP, Chen ZY. Inhibitory effects of jasmine green tea epicatechin isomers on free radical-induced lysis of red blood cells. Life Sciences. 61(4), 1997, 383-94.
  50. [50]. Constable A, Varga N, Richoz J, Stadler RH. Antimutagenicity and catechin content of soluble instant teas. Mutagenesis. 11(2), 1996, 189-94.
  51. [51]. Anderson JW, Diwadkar VA, Bridges SR. Selective effects of different antioxidants on oxidation of lipoproteins from rats. Proceedings of the Society for Experimental Biology and Medicine. 218(4), 1998, 376-81.
  52. [52]. Yamanaka N, Oda O, Nagao S. Green tea catechins such as (-)-epicatechin and (-)-epigallocatechin accelerate copper-induced low-density lipoprotein oxidation in propagation phase. FEBS Letters. 401(2-3), 1997, 230-4.
  53. [53]. Yokozawa T, Dong E. Influence of green tea and its three major components upon low-density lipoprotein oxidation. Experimental and Toxicologic Pathology. 49(5), 1997, 329-35.
  54. [54]. Princen HM, van Duyvenvoorde W, Buytenhek R, Blonk C, Tijburg LB, Langius JA, Meinders AE, Pijl H. No effect of consumption of green and black tea on plasma lipid and antioxidant levels and on LDL oxidation in smokers.Arteriosclerosis, Thrombosis, and Vascular Biology. 18(5), 1998, 833-41.
  55. [55]. Van het Hof KH, de Boer HS, Wiseman SA, Lien N, Westrate JA, Tijburg LB. Consumption of green or black tea does not increase resistance of low-density lipoprotein to oxidation in humans. American Journal of Clinical Nutrition. 66(5), 1997, 1125-32.
  56. [56]. Imai K, Nakachi K. Cross-sectional study of effects of drinking green tea on cardiovascular and liver disease. BMJ. 310, 1995, 693-6.
  57. [57]. Dr.Murtadha Al-Shareifi e-Library Lippincott’s Illustrated Reviews: Pharmacology
  58. [58]. LalitaKunlawong, NatsudaPonwiang, UbonwanJaihan, SomdetSrichairatanakool, ChairatUthaipibull, and VoravuthSomsak Anti-Hemolytic Effects of Green and Black Tea Aqueous Extracts on Plasmodium berghei-Infected Mice Advanced Natural Products 1 (1–6), 2014.
  59. [59]. ChonthidaThephinlap, KanjanaPangjit, Maitree Suttajit1 and SomdetSrichairatanakool., Journal of Medicinal Plants Research Anti-oxidant properties and anti-hemolytic activity ofPsidiumguajava, Pandanousodorus and Rhinacanthusnasutus 3, 2002.